186 related articles for article (PubMed ID: 38090560)
1. Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Mei P; Feng W; Zhan Y; Guo X
Front Immunol; 2023; 14():1321584. PubMed ID: 38090560
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors.
Wan L; Wu C; Luo S; Xie X
Dis Markers; 2022; 2022():3610038. PubMed ID: 36590752
[TBL] [Abstract][Full Text] [Related]
3. The value of lymphocyte to monocyte ratio in the prognosis of head and neck squamous cell carcinoma: a meta-analysis.
Wei D; Liu J; Ma J
PeerJ; 2023; 11():e16014. PubMed ID: 37719125
[TBL] [Abstract][Full Text] [Related]
4. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor.
Chen Y; Zhang C; Peng Z; Qi C; Gong J; Zhang X; Li J; Shen L
Front Oncol; 2021; 11():589022. PubMed ID: 34141607
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis.
Lee SF; Ng TY; Spika D
BMC Cancer; 2019 Apr; 19(1):338. PubMed ID: 30971203
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: a meta-analysis.
Wang Y; Xu C; Zhang Z
BMC Med; 2023 Dec; 21(1):486. PubMed ID: 38053096
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of lymphocyte to monocyte ratio in pancreatic cancer: a systematic review and meta-analysis including 3338 patients.
Lin S; Fang Y; Mo Z; Lin Y; Ji C; Jian Z
World J Surg Oncol; 2020 Jul; 18(1):186. PubMed ID: 32711514
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Lung Cancer: A Systematic Review and Meta-Analysis.
Jin J; Yang L; Liu D; Li WM
Technol Cancer Res Treat; 2021; 20():1533033820983085. PubMed ID: 33576324
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.
Cao J; Chen Q; Bai X; Liu L; Ma W; Lin C; Lu F; Zhou T; Zhan J; Huang Y; Yang Y; Luo F; Zhao H
Ann Med; 2023; 55(2):2280002. PubMed ID: 38065623
[TBL] [Abstract][Full Text] [Related]
10. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Xiang Q; Liu Y; Xiao J; Ou L; Du J
Am J Mens Health; 2024; 18(2):15579883241234747. PubMed ID: 38514969
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis.
Nishijima TF; Muss HB; Shachar SS; Tamura K; Takamatsu Y
Cancer Treat Rev; 2015 Dec; 41(10):971-8. PubMed ID: 26481060
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis.
Gong J; Jiang H; Shu C; Hu MQ; Huang Y; Liu Q; Li RF
J Ovarian Res; 2019 May; 12(1):51. PubMed ID: 31151469
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of lymphocyte to monocyte ratio in patients with gastric cancer: A meta-analysis.
Ma JY; Liu Q
Int J Surg; 2018 Feb; 50():67-71. PubMed ID: 29329786
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis.
Mao Y; Chen D; Duan S; Zhao Y; Wu C; Zhu F; Chen C; Chen Y
Cancer Cell Int; 2018; 18():201. PubMed ID: 30534002
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Zhang S; Qiu C; Yu H; Xu Y; Xu X
Front Oncol; 2023; 13():1070019. PubMed ID: 37143942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
